Cumberland Pharmaceuticals

Cumberland Pharmaceuticals is a specialty pharmaceutical company that acquires, develops and commercializes branded prescription products designed to improve quality of care and address unmet medical needs.
With a focus on underserved niche markets, including hospital acute care and gastroenterology, we deliver products that serve patients in the U.S. market. Cumberland also makes its products available to patients internationally through select strategic partnerships.
We own the worldwide rights to all our brands. While Cumberland’s commercial capabilities are focused on the U.S. market, our business development team is actively pursuing opportunities to make our brands available to patients in markets around the globe.
Our primary mission is to improve upon patient care with products that offer clear advantages over existing treatments. We also strive to deliver solutions that may help reduce costs for healthcare providers and, ultimately, patients.

Type
Public
HQ
Nashville, US
Founded
1999
Size (employees)
82 (est)+6%
Cumberland Pharmaceuticals was founded in 1999 and is headquartered in Nashville, US

Cumberland Pharmaceuticals Office Locations

Cumberland Pharmaceuticals has an office in Nashville
Nashville, US (HQ)
950 2525 West End Ave

Cumberland Pharmaceuticals Metrics

Cumberland Pharmaceuticals Financial Metrics

Revenue (2016)

$33 m

Revenue growth (2015-16), %

3570%

Gross profit

$27.1 m

Gross profit margin (2016), %

82%

Net income (2016)

($1 m)

Market capitalization (21-Mar-2017)

$98.4 m

Closing share price (21-Mar-2017)

$6.4

Cash (31-Dec-2016)

$34.5 m
Cumberland Pharmaceuticals's current market capitalization is $98.4 m.
Cumberland Pharmaceuticals's revenue was reported to be $33 m in 2016
FY, 2013FY, 2014FY, 2015Y, 2016

Revenue

$32 m$36.9 m$900 k$33 m

Revenue growth, %

15%(98%)3570%

Cost of goods sold

$5.4 m$5.1 m$5 m$6 m

Gross profit

$26.6 m$31.8 m($4.1 m)$27.1 m

Gross profit Margin, %

83%86%(452%)82%

Sales and marketing expense

$14.4 m$14.9 m

R&D expense

$5.6 m$3.4 m

General and administrative expense

$9.5 m$8.4 m

Operating expense total

$35.8 m$33.3 m$32.4 m$34.5 m

EBIT

($3.8 m)$3.6 m$1.1 m($1.4 m)

EBIT margin, %

(12%)10%124%(4%)

Interest expense

$103.4 k$67.1 k$73.9 k$106.4 k

Interest income

$230.3 k$251.4 k$209.2 k$204.7 k

Pre tax profit

($3.7 m)$3.7 m$1.2 m($1.3 m)

Income tax expense

($1.5 m)$1.4 m($575.8 k)$330.9 k

Net Income

($2.2 m)$2.4 m$671.1 k($1 m)
FY, 2013FY, 2014FY, 2015FY, 2016

Cash

$40.9 m$39.9 m$38.2 m$34.5 m

Accounts Receivable

Inventories

$5.7 m$5.6 m$4.3 m$5.4 m

Current Assets

$68.7 m$70.8 m$67.1 m$65.5 m

PP&E

$880.6 k$651 k$536.5 k$464.5 k

Total Assets

$87.6 m$95.4 m$91.9 m$93.4 m

Accounts Payable

$2 m$3.2 m$2.9 m$8 m

Current Liabilities

$7.5 m$13.7 m$12.4 m$14.8 m

Retained Earnings

$16.4 m$18.8 m$19.5 m$18.6 m

Total Equity

$79.3 m$80.8 m$76.8 m$73.1 m

Financial Leverage

1.1 x1.2 x1.2 x1.3 x
FY, 2013FY, 2014FY, 2015FY, 2016

Net Income

($2.2 m)$2.4 m$671.1 k($1 m)

Depreciation and Amortization

$1.3 m$2 m$2.2 m$2.4 m

Accounts Receivable

$1.5 m($974.3 k)($572.4 k)($1.3 m)

Inventories

$495.5 k$1.5 m$1.3 m($1.1 m)

Accounts Payable

$1.5 m$191.9 k

Cash From Operating Activities

$746.1 k$6.7 m$5.9 m$569.5 k

Purchases of PP&E

($97.4 k)($163.3 k)($143 k)($130.9 k)

Cash From Investing Activities

($5.1 m)($6 m)($2.3 m)($3.1 m)

Cash From Financing Activities

($9.2 m)($1.7 m)($5.2 m)($1.1 m)

Interest Paid

$79.3 k$28.4 k$27.4 k$21.9 k

Income Taxes Paid

($129.5 k)$17.1 k$52.2 k($8.4 k)

Cumberland Pharmaceuticals Market Value History

Cumberland Pharmaceuticals Company Life

You may also be interested in